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A call for transparent reporting to
optimize the predictive value of
preclinical research
StoryC. Landis1, SusanG.Amara2,KhusruAsadullah3, Chris P.Austin4, RobiBlumenstein5, EileenW.Bradley6, RonaldG.Crystal7,
Robert B. Darnell8, Robert J. Ferrante9, Howard Fillit10, Robert Finkelstein1, Marc Fisher11, Howard E. Gendelman12,
Robert M. Golub13, John L. Goudreau14, Robert A. Gross15, Amelie K. Gubitz1, Sharon E. Hesterlee16, David W. Howells17,
John Huguenard18, Katrina Kelner19, Walter Koroshetz1, Dimitri Krainc20, Stanley E. Lazic21, Michael S. Levine22,
Malcolm R. Macleod23, John M. McCall24, Richard T. Moxley III25, Kalyani Narasimhan26, Linda J. Noble27, Steve Perrin28,
John D. Porter1, Oswald Steward29, Ellis Unger30, Ursula Utz1 & Shai D. Silberberg1
The US National Institute of Neurological Disorders and Stroke convened major stakeholders in June 2012 to discuss
how to improve the methodological reporting of animal studies in grant applications and publications. The main
workshop recommendation is that at a minimum studies should report on sample-size estimation, whether and how
animals were randomized, whether investigators were blind to the treatment, and the handling of data. We recognize
that achieving a meaningful improvement in the quality of reporting will require a concerted effort by investigators,
reviewers, funding agencies and journal editors. Requiring better reporting of animal studies will raise awareness of the
importance of rigorous study design to accelerate scientific progress.
D issemination of knowledge is the engine that drives scientificprogress. Because advances hinge primarily on previous obser-vations, it is essential that studies are reported in sufficient detail
to allow the scientific community, research funding agencies and disease
advocacy organizations to evaluate the reliability of previous findings.
Numerous publications have called attention to the lack of transparency
in reporting, yet studies in the life sciences in general, and in animals in
particular, still often lack adequate reporting on the design, conduct and
analysis of the experiments. To develop a plan for addressing this critical
issue, the US National Institute of Neurological Disorders and Stroke
(NINDS) convened academic researchers and educators, reviewers,
journal editors and representatives from funding agencies, disease advo-
cacy communities and the pharmaceutical industry to discuss the causes
of deficient reporting and how they can be addressed. The specific goal
of the meeting was to develop recommendations for improving how the
results of animal research are reported in manuscripts and grant appli-
cations. There was broad agreement that: (1) poor reporting, often
associated with poor experimental design, is a significant issue across
the life sciences; (2) a core set of research parameters exist that should be
addressed when reporting the results of animal experiments; and (3) a
concerted effort by all stakeholders, including funding agencies and
journals, will be necessary to disseminate and implement best reporting
practices throughout the research community. Here we describe the
impetus for the meeting and the specific recommendations that were
generated.
Widespread deficiencies in methods reporting
In the life sciences, animals are used to elucidate normal biology, to
improveunderstandingof diseasepathogenesis, and todevelop therapeutic
interventions. Animal models are valuable, provided that experiments
employing them are carefully designed, interpreted and reported. Several
recent articles, commentaries and editorials highlight that inadequate
experimental reporting can result in such studies being un-interpretable
and difficult to reproduce1–8. For instance, replication of spinal cord injury
studies through anNINDS-fundedprogramdetermined thatmany studies
could not be replicated because of incomplete or inaccurate description
of experimental design, especially how randomization of animals to the
various test groups, group formulation and delineation of animal attri-
tion and exclusion were addressed7. A review of 100 articles published in
Cancer Research in 2010 revealed that only 28% of papers reported that
animals were randomly allocated to treatment groups, just 2% of papers
reported that observers were blinded to treatment, and none stated the
methods used to determine the number of animals per group, a deter-
mination required to avoid false outcomes2. In addition, analysis of several
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hundred studies conducted in animalmodels of stroke, Parkinson’s disease
andmultiple sclerosis also revealed deficiencies in reporting keymethodo-
logical parameters that can introduce bias6. Similarly, a review of 76 high-
impact (cited more than 500 times) animal studies showed that the pub-
lications lacked descriptions of crucial methodological information that
would allow informed judgment about the findings9. These deficiencies in
the reporting of animal study design, which are clearly widespread, raise
the concern that the reviewers of these studies couldnot adequately identify
potential limitations in the experimental design and/or data analysis, lim-
iting the benefit of the findings.
Some poorly reported studies may in fact be well-designed and well-
conducted, but analysis suggests that inadequate reporting correlates
with overstated findings10–14. Problems related to inadequate study
design surfaced early in the stroke research community, as investigators
tried to understand why multiple clinical trials based on positive results
in animal studies ultimately failed. Part of the problem is, of course, that
no animal model can fully reproduce all the features of human stroke.
It also became clear, however, that many of the difficulties stemmed
from a lack of methodological rigor in the preclinical studies that were
not adequately reported15. For instance, a systematic review and meta-
analysis of studies testing the efficacy of the free-radical scavenger NXY-
059 in models of ischaemic stroke revealed that publications that
included information on randomization, concealment of group alloca-
tion, or blinded assessment of outcomes reported significantly smaller
effect sizes of NXY-059 in comparison to studies lacking this informa-
tion10. In certain cases, a series of poorly designed studies, obscured by
deficient reporting, may, in aggregate, serve erroneously as the scientific
rationale for large, expensive and ultimately unsuccessful clinical trials.
Such trials may unnecessarily expose patients to potentially harmful
agents, prevent these patients fromparticipating in other trials of possibly
effective agents, and drain valuable resources and energy that might
otherwise be more productively spent.
A core set of reporting standards
The large fraction of poorly reported animal studies and the empirical
evidence of associated bias6,10–14,16–20, defined broadly as the introduction
of an unintentional difference between comparison groups, led various
disease communities to adopt general21–23 and animal-model-specific6,24–26
reporting guidelines. However, for guidelines to be effective and broadly
accepted by all stakeholders, they should be universal and focus onwidely
accepted core issues that are important for study evaluation. Therefore,
based on available data, we recommend that, at minimum, authors of
grant applications and scientific publications should report on randomi-
zation, blinding, sample-size estimation and the handling of all data (see
below and Box 1).
Randomization and blinding
Choices made by investigators during the design, conduct and inter-
pretation of experiments can introduce bias, resulting in false-positive
results. Many have emphasized the importance of randomization and
blinding as a means to reduce bias6,21–23,27, yet inadequate reporting of
these aspects of study design remains widespread in preclinical research.
It is important to report whether the allocation, treatment and handling
of animals were the same across study groups. The selection and source
of control animals needs to be reported as well, including whether they
are true littermates of the test groups. Best practices should also include
reporting on the methods of animal randomization to the various
experimental groups, as well as on random (or appropriately blocked)
sample processing and collection of data. Attention to these details will
avoidmistaking batch effects for treatment effects (for example, dividing
samples from a large study into multiple lots, which are then processed
separately). Investigators should also report on whether the individuals
caring for the animals and conducting the experiments were blinded to
the allocation sequence, blinded to group allocation and, whenever
possible, whether the persons assessing, measuring or quantifying the
experimental outcomes were blinded to the intervention.
Sample-size estimation
Minimizing the use of animals in research is not only a requirement of
funding agencies around the world but also an ethical obligation. It is
unethical, however, to perform underpowered experiments with insuf-
ficientnumbers of animals that have little prospect of detectingmeaningful
differences between groups. In addition, with smaller studies, the positive
predictive value is lower, and false-positive results can ensue, leading to the
needless use of animals in subsequent studies that build upon the incorrect
results28. Studies with an inadequate sample size may also provide false-
negative results, where potentially important findings go undetected. For
these reasons it is crucial to report howmany animals were used per group
and what statistical methods were used to determine this number.
Data handling
Common practices related to data handling that can also lead to false
positives include interim data analysis29, the ad hoc exclusion of data30,
retrospective primary end point selection31, pseudo replication32 and
small effect sizes33.
Interim data analysis
It is not uncommon for investigators to collect some data and perform
an interim data analysis. If the results are statistically significant in
favour of the working hypothesis, the study is terminated and a paper
BOX 1
A core set of reporting standards
for rigorous study design
Randomization
NAnimals should be assigned randomly to the various experimental
groups, and the method of randomization reported.
NData shouldbe collected andprocessed randomly or appropriately
blocked.
Blinding
NAllocation concealment: the investigator should be unaware of the
group to which the next animal taken from a cage will be allocated.
NBlinded conduct of the experiment: animal caretakers and
investigators conducting the experiments should be blinded to the
allocation sequence.
NBlinded assessment of outcome: investigators assessing,
measuring or quantifying experimental outcomes should be
blinded to the intervention.
Sample-size estimation
NAn appropriate sample size should be computedwhen the study is
beingdesignedandthestatisticalmethodofcomputationreported.
NStatistical methods that take into account multiple evaluations of
the data should be used when an interim evaluation is carried out.
Data handling
NRules for stopping data collection should be defined in advance.
NCriteria for inclusion and exclusion of data should be established
prospectively.
NHow outliers will be defined and handled should be decided when
the experiment is being designed, and any data removed before
analysis should be reported.
NTheprimary end point should be prospectively selected. Ifmultiple
end points are to be assessed, then appropriate statistical
corrections should be applied.
NInvestigators should report on data missing because of attrition or
exclusion.
NPseudo replicate issues need tobe consideredduring studydesign
and analysis.
NInvestigators should report how often a particular experiment was
performed and whether results were substantiated by repetition
under a range of conditions.
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is written. If the results look ‘promising’ but are not statistically signifi-
cant, additional data are collected. This has been referred to as ‘sampling
to a foregone conclusion’ and can lead to a high rate of false-positive
findings29,30. Therefore, sample size and rules for stopping data collec-
tion should be defined in advance and properly reported. Unplanned
interim analyses, which can inflate false-positive outcomes and require
unblinding of the allocation code, should be avoided. If there are interim
analyses, however, these should be reported in the publication.
Ad hoc exclusion of data
Animal studies are often complex and outliers are not unusual.
Decisions to include or exclude specific animals on the basis of outcomes
(for example, state of health, dissimilarity to other data) have the poten-
tial to influence the study results. Thus, rules for inclusion and exclusion
of data should be defined prospectively and reported. It is also important
to report whether all animals that were entered into the experiment
actually completed it, or whether they were removed, and if so, for what
reason. Differential attrition between groups can introduce bias. For
example, a treatment may appear effective if it kills off the weakest or
most severely affected animals whose fates are then not reported. In
addition, it is important to report whether any data were removed before
analysis and the reasons for this data exclusion.
Retrospective primary end-point selection
It is well known that assessment of multiple end points, and/or assess-
ment of a single end point at multiple time points, inflates the type-I
error (false-positive results)31. Yet it is not uncommon for investigators
to select a primary end point only after data analyses. False-positive
conclusions arising from such practices can be avoided by specifying a
primary end point before the study is undertaken, the time(s) at which
the end point will be assessed, and the method(s) of analysis. Significant
findings for secondary end points can and should be reported, but
should be delineated as exploratory in nature. If multiple end points
are to be assessed, then appropriate statistical corrections should be
applied to control type-I error, such as Bonferroni corrections31,34.
Pseudo replicates
When considering sample-size determination and experimental design,
pseudo-replication issues need to be considered32. There is a clear, but
often misunderstood or misrepresented, distinction between technical
and biologic replicates. For example, in analysing effects of pollutants on
reproductive health, multiple sampling from a litter, regardless of
how many littermates are quantified, provides data from only a single
biologic replicate.When biologic variation in response to some interven-
tion is the variable of interest, as inmany animal experiments, analysis of
samples from multiple litters is essential. The unit of assessment is the
smallest unit (animal, cage, litter) to which the intervention in question
can be independently administered35.
Small effect sizes
A statistically significant result does not provide information on the
magnitude of the effect and thus does not necessarily mean that the
effect is robust, which could account for the poor reproducibility of certain
studies36. Therefore, reportingwhether results were substantiated by repe-
tition, preferably under a range of conditions that demonstrate the robust-
ness of the effect is encouraged. Also, reporting how often the particular
experiment was performed as ameans to control for a general tendency to
publish only the best results would strengthen the validity of experimental
results. To this end, carefully designed and powered animal studies should
be budgeted for in the grant applications and funding agencies should
consider supporting repetition studies where appropriate.
An important note about exploratory experiments
For the most part, these best practices do not apply to early-stage obser-
vational experiments searching for possible differences among experi-
mental groups. Such exploratory testing is frequently conducted using a
small sample size, does not have a primary outcome and is often
unblinded. However, because such experiments are likely to be subject
to many of the limitations described above, they should be viewed as
hypothesis-generating experiments and interpreted as such. Potential
discoveries arising from the exploratory phase of the research should be
supported by follow-up, hypothesis-testing experiments that take into
consideration and adequately report on the core standards detailed
above (Box 1).
The path to implementation
Improving the transparency and quality of reporting cannot be achieved
by a single party, but will require cooperation among all stakeholders,
including investigators, reviewers, funding agencies and journals.
Calling upon investigators to provide key information about the design,
execution and analysis of animal experiments described in grant appli-
cations and manuscripts and encouraging reviewers to consider these
issues in their evaluations should, over time, increase both the quality
and predictive value of preclinical research. Potential strategies for
achieving this goal can be adopted from the clinical trials community,
which also contended with poor reporting and associated bias. Evidence
that clinical trials can yield biased results if they lack methodological
rigor37–42 led to the development and implementation of the CONSORT
guidelines for randomized clinical trials (among other guidelines), now
adopted by many clinical journals and funding organizations. These
guidelines require that authors reportwhether andhow their studieswere
carried out blind and randomized, how sample size was determined,
whether data are missing owing to attrition or exclusion, and supply
information about other important experimental parameters43–45.
Importantly, the guidelines have improved the transparency of clinical
study reporting in journals that have adopted them46–49. Additional evid-
ence for the power of such guidelines can be deduced from the obser-
vation that, although few animal studies report on randomization,
blinding or sample-size determination, most describe compliance with
animal regulations, which is required by journals6,9,10,50,51.
As a first step, we recommend that funding organizations and journals
provide reviewerswith clear guidance about core features of animal study
design (listed in Box 1). The goal is not to be prescriptive or proscrip-
tive, but rather to delineate the minimum set of standards that should
routinely be considered in evaluating the appropriateness of a study. Such
guidance would make the task easier for reviewers of manuscripts and
grant applications who volunteer their time and are often overextended.
In addition, investigators and reviewers should be encouraged to consult
published generic and model-specific guidelines for designing in vivo
animal experiments6,21–27,52,53. To assist reviewers, editors and funding
organizations in making sure that applications and manuscripts contain
sufficient information on the core reporting recommendation (Box 1),
authors could be asked to append relevant information on a standardized
form that accompanies the submission. This form could be as simple as a
checkbox indicating the page on which the key reporting standard is
addressed. Such a form is currently used by clinical research journals.
In addition to the measures proposed above, better dissemination
of knowledge will be greatly facilitated by addressing publication bias,
the phenomenon that few studies showing negative outcomes are
published54–63. Such deficiency in reporting contributes to needless repe-
tition of similar studies by investigators unaware of earlier efforts60,61.
There is a widely accepted belief that the scientific community, promo-
tions committees, funding agencies and journals favour positive out-
comes, an impression that can lead to bias64. Possible solutions include
incentivizing investigators to publish negative outcomes, supporting
studies of independent replication, encouraging journals to publish a
greater number of studies reporting negative outcomes, creating a data-
base for negative outcomes (analogous to http://ClinicalTrials.gov/),
and linking the raw data to publications.
Change will not occur overnight. The importance of training scientists
to properly design and adequately report animal studies cannot be over-
stated. Training and education focused on key features of experimental
PERSPECTIVE RESEARCH
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design should be an ongoing process for both the novice and veteran
involved in biomedical research. Attention to better study design reporting
should be communicated at major meetings, brought to the attention of
reviewers, editors and funders, required by the publishers of peer-review
journals, and included in the training program of graduate and postdoc-
toral students. Furthermore, good mentorship is crucial for developing
such skills and should be encouraged and rewarded. Rigorous experi-
mental design and adequate reporting needs to be emphasized across the
board and monitored in training grants awarded by the US National
Institute of Health (NIH) and other funding agencies. Professional soci-
eties can also have an important role by highlighting this issue in their
respective communities.
An important gatekeeper of quality remains the peer review of grant
applications and journal manuscripts. We therefore call upon funding
agencies and publishing groups to take actions to reinforce the import-
ance of methodological rigor and reporting. NINDS has begun taking
steps to promote best practices for preclinical therapy development
studies. In 2011, a Notice was published in the NIH Guide encouraging
the scientific community to address the issues described above in their
grant applications, in describing both the project being proposed and the
supporting data upon which it is based (http://grants.nih.gov/grants/
guide/notice-files/NOT-NS-11-023.html). Points that should be consid-
ered in a well-designed study are listed on the NINDS website (http://
www.ninds.nih.gov/funding/transparency_in_reporting_guidance.pdf).
Furthermore, the reviewers of applications reviewed by the NINDS
Scientific Review Branch are reminded of these issues and asked to pay
careful attention to the scientific premise of the proposed projects.
We believe that improving how animal studies are reported will raise
awareness of the importance of rigorous study design. Such increased
awareness will accelerate both scientific progress and the development
of new therapies.
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